[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Community Pharmacology Services Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100550422","menopausal-symptoms-probiotic-study-100550422",false,"NCT06446869","Menopausal Symptoms Probiotic Study","Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the Combination of Levilactobacillus Brevis KABP-052, Lactiplantibacillus Plantarum KABP-051 and Pediococcus Acidilactici KABP-021 on Menopausal Symptoms and Quality of Life in Peri- and Post-menopausal Women","Inclusion Criteria:\n\n* Perimenopausal or post-menopausal women with spontaneous menopause and amenorrhoea for less than 2 years\n* Self reported menopausal symptoms (5 or more hot flashes\u002Fnight sweats per day or 35 or more per week recorded daily for 14 consecutive days)\n* BMI between 18.5 and 34.9 kg\u002Fm2\n* Menopause rating score II (MRS-II) total score of 9 or more at baseline visit\n* Willing to sign Informed Consent Form\n* Willing to not make relevant changes to their current dietary or lifestyle habits during study\n* Able to follow study procedures\n* If perimenopausal, agrees to use an accepted method of contraception for duration of study.\n\nExclusion Criteria:\n\n* History of hysterectomy, oophorectomy, endometrial hyperplasia, uterine or endometrial cancer, breast cancer, or cancers associated with sex hormones\n* Use of hormonal replacement therapy, hormone analogues, or oral contraceptives within 3 months prior to the start of the study\n* Intake of herbal or food supplements with known effects on menopause symptoms within 1 month prior to the start of the study. Examples of prohibited substances are black cohosh, melatonin, ginseng, chasteberry, phytoestrogens (e.g., hop \\[Humulus lupulus L.\\], soy isoflavones, red clover) within 1 month prior to the start of the study\n* Use of any food supplement containing probiotics or postbiotics or regular consumption (\\>3 days\u002Fweek) of foods containing probiotics (including yogurt with added probiotics or bifidus effect) within 1 month prior to the start of the study\n* Use of oral (\\>3 days) or parenteral antibiotics within 1 month prior to the start of the study\n* Participants with a new diagnosis of mental health disorder in the last 12 months or with an unstable or uncontrolled mental health disorder in the opinion of the Investigator\n* Diagnosis of type 1 or uncontrolled type 2 diabetes mellitus\n* Diagnosis of chronic gastrointestinal disease, such as inflammatory bowel disease (Crohn's disease or ulcerative colitis), pancreatitis, or short bowel syndrome\n* History of thyroid disorders (hypothyroidism or hyperthyroidism) which are untreated or unstable\n* History of gastrointestinal surgery 6 months prior to the start of the study, with the exception of appendicectomy\n* Regular intake (\\>3 days\u002Fweek) of medication that affects microbiota or bowel movements, namely laxatives like polyethylene glycol or stimulant laxatives (bisacodyl, sennosides, sodium pyrosulfate)\n* History of coronary disease, myocardial infarction, unstable angina, or previous coronary angioplasty\n* History of venous thromboembolism (VTE) or known to be high risk for VTE due to inherited or acquired thrombophilia (such as factor V Leiden, antiphospholipid syndrome)\n* History of stroke or transient ischaemic attack\n* History of severe renal dysfunction as defined by an estimated glomerular filtration rate \\\u003C30 mL\u002Fminute or severe liver dysfunction defined as established cirrhosis or active liver disease with alanine aminotransferase (ALT) \\>3 × upper limit of normal at baseline\n* Initiated for new diagnosis or changed dose of UK-approved therapeutic medication or nutraceuticals for a medical condition that can affect study outcomes according to the Investigator's judgement (i.e., statins, anti-hypertensives, etc.) within 90 days prior to study entry\n* Diagnosis of primary or secondary immunodeficiency including acquired immunodeficiency syndrome, immunodeficiency, or active oncologic disease\n* Known or suspected alcohol or drug abuse\n* Any other surgical or medical condition, which in the opinion of the Investigator, may place the participant at higher risk from her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study\n* Currently participating in another study or having participated in one within 3 months prior to the start of the study\n* The participant is pregnant, planning a pregnancy, or breastfeeding","FEMALE","42 Years","60 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this study, we want to investigate if the active product consisting of a probiotic blend can potentiate the recirculation of active oestrogens into the bloodstream and help to mitigate menopause symptoms, which are closely related to oestrogens levels",[27],"Menopause",[29,30,31,32,33],"menopause","menopausal symptoms","hot flashes","night sweats","menopause treatment","RECRUITING","2026-01-23",{"date":37,"type":38},"2026-01-26","ACTUAL",{"date":40,"type":38},"2024-09-10",{"date":42,"type":21},"2026-10-25",{"name":44,"class":45},"Community Pharmacology Services Ltd","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":5},"100497837","diabetic-foot-ulcer-research-study-100497837","NCT05762432","Diabetic Foot Ulcer Research Study","A Pilot Open Label Prospective, Randomised, Study to Evaluate the Safety and Efficacy of Keneric Healthcare RTD Wound Dressing in the Treatment of Diabetic Foot Ulcers Compared to Standard of Care","Inclusion Criteria:\n\n* Male or female, aged ≥18 years old with a diagnosis of type 1 or type 2 diabetes.\n* New presentation for treatment of a neuropathic, ischaemic or neuro- ischaemic non- infected DFU\n* Subjects must be able to follow verbal and written instructions in English\n* Subjects must have full mental capacity and able to give written informed consent to participation in the trial including medical photography for the purposes of the clinical trial or clinical care.\n* DFU is \\>10mm2 and \\\u003C100mm2\n\nExclusion Criteria:\n\n* Known allergy\u002Fhypersensitivity to any ingredient contained in the Keneric healthcare RTD Wound Dressing\n* Participants who will have problems following the protocol, including the offloading system, provided as standard of care, to wear on a daily basis\n* Suspected malignancy in the wound\n* Critical limb ischaemia\n* Pregnant or breastfeeding females\n* Women of childbearing potential and not using a medically accepted form of contraception when sexually active.","ALL","18 Years",{"count":57,"type":21},100,[24],"The goal of this clinical trial is to compare safety and performance of the study device to the current typical NHS standards of care device. The main outcomes it aims to achieve are:\n\nComplete wound healing at 12 weeks (100% epithelialised)\n\n% Reduction in wound area at 12 weeks\n\nParticipants will attend their NHS podiatry clinic appointment as normal and will be assigned either the study device or the current typical NHS standard of care device. Researchers will compare the study device group to the standard group to assess the outcomes mentioned previously.",[61,62,63],"Diabetic Foot Ulcer","Diabetic Foot Ulcer Neuropathic","Diabetic Foot Ulcer Ischemic",[65,66,61],"Diabetes","Foot Ulcer",{"date":37,"type":38},{"date":69,"type":38},"2024-04-26",{"date":71,"type":21},"2027-01-01",{"name":44,"class":45},""]